A Systematic Review and Meta-Analysis of the Relationship Between the Radiation Absorbed Dose to the Thyroid and Response in Patients Treated with Radioiodine for Graves' Disease

Overview

Journal Thyroid

Date 2021 Oct 2

PMID 34598656

Citations 6

Authors

Jan Taprogge

Paul M D Gape

Lily Carnegie-Peake

Iain Murray

Jonathan I Gear

Francesca Leek

Steve L Hyer

Glenn D Flux

Affiliations

Soon will be listed here.

Abstract

Patients with Graves' disease are commonly treated with radioiodine. There remains controversy over whether the aim of treatment should be to achieve euthyroidism or hypothyroidism, and whether treatments should be administered with standard levels of radioactivity or personalized according to the radiation absorbed doses delivered to the thyroid. The aim of this review was to investigate whether a relationship exists between radiation absorbed dose and treatment outcome. A systematic review and meta-analysis of all reports published before February 13, 2020, were performed using PubMed, Web of Science, OVID MEDLINE, and Embase. Proportion of patients achieving nonhyperthyroid status was the primary outcome. Secondary outcomes were proportion of patients who were specifically euthyroid or hypothyroid. A random-effects meta-analysis of proportions was performed for primary and secondary outcomes, and the impact of the radiation absorbed dose on treatment outcome was assessed through meta-regression. The study is registered with PROSPERO (CRD42020175010). A total of 1122 studies were identified of which 15, comprising 2303 Graves' disease patients, were eligible for the meta-analysis. A strong association was found between radiation absorbed dose and nonhyperthyroid and hypothyroid outcomes (odds ratio [OR] = 1.11 [95% confidence interval {CI} 1.08-1.14] and OR = 1.09 [CI 1.06-1.12] per 10 Gy increase). Higher rates of euthyroid outcome were found for radiation absorbed doses within the range 120-180 Gy when compared with outside this range ( = 1172, OR = 2.50 [CI 1.17-5.35], = 0.018). A maximum euthyroid response of 38% was identified at a radiation absorbed dose of 128 Gy. The presented radiation absorbed dose-response relationships can facilitate personalized treatment planning for radioiodine treatment of patients with Graves' disease. Further studies are required to determine how patient-specific covariates can inform personalized treatments.

Citing Articles

Predictive Performance of 2 Immunoassays in Patients with Graves Disease Undergoing Radioiodine Therapy: Prospective Study.

de Souza M, Sapienza M, Brito L, Cortez P, Marui S J Endocr Soc. 2025; 9(3):bvaf016.

PMID: 39935695 PMC: 11811413. DOI: 10.1210/jendso/bvaf016.

Gamma camera-specific reference standards for radioactive iodine uptake measurements.

Mourik J, Derks M, Te Beek E, Ten Broek M EJNMMI Phys. 2023; 10(1):55.

PMID: 37702889 PMC: 10499732. DOI: 10.1186/s40658-023-00575-2.

The EANM guideline on radioiodine therapy of benign thyroid disease.

Campenni A, Avram A, Verburg F, Iakovou I, Hanscheid H, de Keizer B Eur J Nucl Med Mol Imaging. 2023; 50(11):3324-3348.

PMID: 37395802 PMC: 10542302. DOI: 10.1007/s00259-023-06274-5.

Quantification and dosimetry of small volumes including associated uncertainty estimation.

Carnegie-Peake L, Taprogge J, Murray I, Flux G, Gear J EJNMMI Phys. 2022; 9(1):86.

PMID: 36512147 PMC: 9748012. DOI: 10.1186/s40658-022-00512-9.

Determinants of target absorbed dose in radionuclide therapy.

Hanscheid H, Lassmann M, Verburg F Z Med Phys. 2022; 33(1):82-90.

PMID: 36376202 PMC: 10068538. DOI: 10.1016/j.zemedi.2022.10.001.

References

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

Mitchell A, Hegedus L, Zarkovic M, Hickey J, Perros P . Patient satisfaction and quality of life in hypothyroidism: An online survey by the british thyroid foundation. Clin Endocrinol (Oxf). 2020; 94(3):513-520. DOI: 10.1111/cen.14340. View

Grosso M, Traino A, Boni G, Banti E, Della Porta M, Manca G . Comparison of different thyroid committed doses in radioiodine therapy for Graves' hyperthyroidism. Cancer Biother Radiopharm. 2005; 20(2):218-23. DOI: 10.1089/cbr.2005.20.218. View

Kobe C, Eschner W, Sudbrock F, Weber I, Marx K, Dietlein M . Graves' disease and radioiodine therapy. Is success of ablation dependent on the achieved dose above 200 Gy?. Nuklearmedizin. 2008; 47(1):13-7. View

Okosieme O, Taylor P, Evans C, Thayer D, Chai A, Khan I . Primary therapy of Graves' disease and cardiovascular morbidity and mortality: a linked-record cohort study. Lancet Diabetes Endocrinol. 2019; 7(4):278-287. DOI: 10.1016/S2213-8587(19)30059-2. View

Ritz C, Baty F, Streibig J, Gerhard D . Dose-Response Analysis Using R. PLoS One. 2015; 10(12):e0146021. PMC: 4696819. DOI: 10.1371/journal.pone.0146021. View

Walter M, Briel M, Christ-Crain M, Bonnema S, Connell J, Cooper D . Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. BMJ. 2007; 334(7592):514. PMC: 1819480. DOI: 10.1136/bmj.39114.670150.BE. View

Blahd W, Hays M . Graves' disease in the male. A review of 241 cases treated with an individually calculated dose of sodium iodide I 131. Arch Intern Med. 1972; 129(1):33-40. DOI: 10.1001/archinte.129.1.33. View

Ross D, Burch H, Cooper D, Greenlee M, Laurberg P, Maia A . 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016; 26(10):1343-1421. DOI: 10.1089/thy.2016.0229. View

10.

Schiavo M, Bagnara M, Calamia I, Bossert I, Ceresola E, Massaro F . A study of the efficacy of radioiodine therapy with individualized dosimetry in Graves' disease: need to retarget the radiation committed dose to the thyroid. J Endocrinol Invest. 2010; 34(3):201-5. DOI: 10.1007/BF03347067. View

11.

Peters H, Fischer C, Bogner U, Reiners C, Schleusener H . Radioiodine therapy of Graves' hyperthyroidism: standard vs. calculated 131iodine activity. Results from a prospective, randomized, multicentre study. Eur J Clin Invest. 1995; 25(3):186-93. DOI: 10.1111/j.1365-2362.1995.tb01547.x. View

12.

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

13.

Kahaly G, Bartalena L, Hegedus L, Leenhardt L, Poppe K, Pearce S . 2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism. Eur Thyroid J. 2018; 7(4):167-186. PMC: 6140607. DOI: 10.1159/000490384. View

14.

Reinhardt M, Brink I, Joe A, von Mallek D, Ezziddin S, Palmedo H . Radioiodine therapy in Graves' disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome. Eur J Nucl Med Mol Imaging. 2002; 29(9):1118-24. DOI: 10.1007/s00259-002-0877-3. View

15.

Oszukowska L, Knapska-Kucharska M, Makarewicz J, Lewinski A . The influence of thiamazole, lithium carbonate, or prednisone administration on the efficacy of radioiodine treatment ((131)I) in hyperthyroid patients. Endokrynol Pol. 2010; 61(1):56-61. View

16.

Howarth D, Epstein M, Lan L, Tan P, Booker J . Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study. Eur J Nucl Med. 2001; 28(10):1489-95. DOI: 10.1007/s002590100621. View

17.

Bockisch A, Jamitzky T, Derwanz R, Biersack H . Optimized dose planning of radioiodine therapy of benign thyroidal diseases. J Nucl Med. 1993; 34(10):1632-8. View

18.

Boelaert K, Syed A, Manji N, Sheppard M, Holder R, Gough S . Prediction of cure and risk of hypothyroidism in patients receiving 131I for hyperthyroidism. Clin Endocrinol (Oxf). 2008; 70(1):129-38. DOI: 10.1111/j.1365-2265.2008.03291.x. View

19.

Schiavo M, Bagnara M, Pomposelli E, Altrinetti V, Calamia I, Camerieri L . Radioiodine therapy of hyperfunctioning thyroid nodules: usefulness of an implemented dose calculation algorithm allowing reduction of radioiodine amount. Q J Nucl Med Mol Imaging. 2013; 57(3):301-7. View

20.

Stokkel M, Handkiewicz Junak D, Lassmann M, Dietlein M, Luster M . EANM procedure guidelines for therapy of benign thyroid disease. Eur J Nucl Med Mol Imaging. 2010; 37(11):2218-28. DOI: 10.1007/s00259-010-1536-8. View